Patients with amino acid mutations including the Thr104Asn (T104N) mutation of CHMP2B have predominantly ALS phenotypes whereas patients with other mutations have predominantly FTD phenotypes [7,8,11]. This evidence concerns the gene CHMP2B and frontotemporal dementia.